P368: A PHASE II STUDY OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF MEASURABLE RESIDUAL DISEASE-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. (23rd June 2022)

Record Type:
Journal Article
Title:
P368: A PHASE II STUDY OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF MEASURABLE RESIDUAL DISEASE-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. (23rd June 2022)
Main Title:
P368: A PHASE II STUDY OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF MEASURABLE RESIDUAL DISEASE-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Authors:
Senapati, J.
Kantarjian, H.
Short, N.
Alvarado, Y.
Burger, J.
Jain, N.
Konopleva, M.
Ravandi, F.
DiNardo, C.
Masarova, L.
Sasaki, K.
Thompson, P. A.
Ferrajoli, A.
Jacob, J. O.
Mayor, E. D.
Milton, A. M.
Loiselle, C.
Garris, R. S.
Jabbour, E. J.
Abstract:
Is Part Of:
HemaSphere. Volume 6(2022)Supplement 3
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Issue Display:
Volume 6, Issue 3 (2022)
Year:
2022
Volume:
6
Issue:
3
Issue Sort Value:
2022-0006-0003-0000
Page Start:
268
Page End:
269
Publication Date:
2022-06-23
Subjects:
Hematology -- Periodicals
616.15005
Journal URLs:
https://journals.lww.com/hemasphere/pages/default.aspx ↗
http://journals.lww.com/pages/default.aspx ↗
DOI:
10.1097/01.HS9.0000844360.06367.63 ↗
Languages:
English
ISSNs:
2572-9241
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
22732.xml